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Introduction 
Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is an autoimmune 
disorder characterised by psychiatric symptoms, movement disorder and seizures 
often evolving into a severe encephalopathy.1 It is characterised by the presence of 
IgG autoantibodies against the NMDAR in CSF and/or serum and predominantly 
affects young women. 1 Despite marked neurological disturbance, only 35-50% of 
patients have abnormal neuroimaging and the course of the disease is typically 
monophasic.2 An overlap has recently been recognised between anti-NMDAR 
encephalitis and inflammatory demyelinating disorders, particularly neuromyelitis 
optical spectrum disorder (NMOSD).3 We describe two patients with an initial 
presentation consistent with anti-NMDAR encephalitis who have subsequently 
developed relapsing-remitting multiple sclerosis (MS).   
Case 1 
A 32 year old woman presented with seizures, abnormal movements affecting the 
right shoulder and encephalopathy. An MRI scan of the brain showed multiple T2-
hyperintense brain and spinal cord lesions typical for demyelination (Figure 1a and 
b). None of the lesions showed enhancement after the administration of gadolinium 
contrast. A cerebrospinal fluid (CSF) examination showed a mild lymphocytic 
pleocytosis (white cell count 12 x 106/L, protein 61mg/dL) and unmatched oligoclonal 
bands not present in serum. Anti-NMDAR antibodies were positive in serum and not 
checked in CSF. A whole body CT-PET scan and pelvic ultrasound showed no 
underlying neoplasm. Attempts at immunotherapy were not tolerated and the 
symptoms partially improved spontaneously but she had persisting cognitive 
impairment.  
  
 
Sixteen months later, she presented with a two week history of double vision, facial 
weakness and cerebellar ataxia in the absence of encephalopathy. Repeat MRI 
brain showed multiple new brain and spinal cord lesions, including a new contrast-
enhancing lesion in the dorsal pons (Figure 1c and d). Anti-NMDAR, anti-aquaporin 
4 (AQP4) and anti-myelin oligodendrocyte glycoprotein (MOG) antibodies were 
negative. She commenced disease-modifying treatment 10 months later and 
remains free of relapses. 
 
Case Two 
A 29 year old man presented with psychosis and seizures. An MRI scan of the brain 
showed T2-hyperintense lesions typical of demyelination (Figure 2a-c) and a CSF 
examination showed unmatched oligoclonal bands. Anti-NMDAR antibodies were 
positive in serum and CSF. No underlying malignancy was identified and his 
symptoms improved spontaneously without immunotherapy. Two years later he 
developed sensory symptoms in the lower limbs ascending to a level on the trunk. 
An MRI scan of the spinal cord showed an area of T2 hyperintensity at the level of 
T11 (Figure 2d). A repeat CSF examination showed persistence of oligoclonal bands 
but negative for anti-NMDAR antibodies. Following the episode of partial myelitis a 
diagnosis of MS was made using the McDonald 2010 criteria. 
 
 
 
  
Discussion  
We report two patients with a clinical phenotype and serology compatible with anti-
NMDAR encephalitis but also asymptomatic T2-hyperintense lesions typical for 
demyelination and positive oligoclonal bands at presentation. Both patients 
developed new neurological symptoms highly suggestive of MS (brainstem 
syndrome, short-segment myelitis), coupled with MRI evidence of dissemination in 
time and space, fulfilling both clinical and radiological criteria for relapsing-remitting 
MS.  
 
The cases described build on the three existing reports of anti-NMDAR encephalitis 
occurring in patients with established MS.4-6 These cases outline patients with 
relapsing-remitting MS who had developed encephalopathy. In two of the previously 
reported cases, a prompt diagnosis was crucial to commence appropriate 
immunotherapy and to avoid neuro-psychiatric deficits. In the other reported case, a 
retrospective diagnosis of NMDAR encephalitis (on saved CSF samples) was made 
six years after a female patient diagnosed with relapsing-remitting MS had presented 
with severe cognitive impairment; despite stabilisation of her condition with 
immunotherapy, she required admission to a nursing home two years after her initial 
presentation.   
 
Another recent case reported the incidental finding of anti-NMDAR antibodies in a 
patient with MS. Despite careful evaluation, he did not demonstrate any features of 
NMDAR encephalitis but was still treated with rituximab.7 In contrast to MS, anti-
  
NMDAR encephalitis may overlap much more frequently with NMOSD.2 In a recent 
large series of 691 patients with anti-NMDAR encephalitis, 3.3% had clinical and/or 
imaging evidence of a demyelinating disorder, usually with features suggestive of 
NMOSD (longitudinally-extensive transverse myelitis, bilateral optic neuritis) and 
most (18 out of 23) had anti-AQP4 or anti-MOG antibodies.3 In half of cases the 
demyelinating events were concurrent with the anti-NMDAR encephalitis and half 
were disseminated in time.3  
An unanswered question is whether the overlap between anti-NMDAR encephalitis 
and the idiopathic inflammatory demyelinating disorders represents a chance 
occurrence or whether they may be mechanistically linked. The reported frequency 
of NMOSD in patients with anti-NMDAR encephalitis in the series described above 
would argue against chance alone, although, any association is in part clouded by 
the high rate of co-morbid autoimmune disorders in patients with NMOSD. Another 
possibility is that inflammatory demyelination may trigger anti-NMDAR encephalitis. 
Recently, anti-NMDAR encephalitis has been identified as a major cause of 
relapsing neurologic symptoms in patients with herpes simplex virus encephalitis 
(HSE), after excluding inadequately treated infection.8 The mechanism by which HSE 
might give rise to parainfectious anti-NMDAR encephalitis is uncertain, but neuronal 
infection and inflammation might expose antigens that generate an autoimmune 
response. Whether inflammatory demyelination might also trigger anti-NMDAR 
encephalitis by a similar mechanism is unclear. 
 
Based on the small number of reports to date, anti-NMDAR encephalitis does not 
appear to commonly overlap with MS. In the largest study to date investigating the 
  
prevalence of anti-NMDAR antibodies in patients with established MS, only 1 of 89 
patients tested was positive and that patient had a history of typical anti-NMDAR 
encephalitis that developed 3 years after the diagnosis of relapsing-remitting MS5.  
 
However our two cases, in conjunction with other reports, suggest that there is a 
degree of overlap between anti-NMDAR encephalitis and MS that is attributable to 
more than chance.  
Encephalopathic relapses, psychosis, severe cognitive impairment and unusual 
movement disorders have all been described people with MS. In settings where 
patients with MS develop unusual symptomatology, testing for anti-NMDAR 
antibodies should be considered in order to guide the most appropriate 
immunotherapy. 
References 
1. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and 
analysis of the effects of antibodies. Lancet Neurol  2008;7:1091-8 
2. Barry H, Byrne S, Barrett E, et al. Anti-NMDAR encephalitis: A review of clinical presentation 
diagnosis and treatment. BJPsych Bull 2015; 39(1): 19–23. 
3. Titulaer MJ, Hoftberger R, Iizuka T, et al. Overlapping demyelinating syndromes and anti-
NMDA receptor encephalitis. Ann Neurol. 2014;75(3):411-28 
4. Uzawa A, Mori M, Takahashi Y, et al. Anti-N-methyl D-aspartate-type glutamate receptor 
antibody-positive limbic encephalitis in a patient with multiple sclerosis. Clin Neurol Neurosurg 
2012;114:402-4 
5. Ramberger M, Bsteh G, Schanda K, et al. NMDA receptor antibodies: A rare association in 
inflammatory demyelinating diseases. Neurology(R) neuroimmunology & neuroinflammation 
2015;2:e141.                                                                                                                                                                                                                         
6. Fleischmann R, Pruss H, Rosche B, et al. Severe cognitive impairment associated with 
intrathecal antibodies to the NR1 subunit of the N-methyl-D-aspartate receptor in a patient with 
multiple sclerosis. JAMA neurology 2015;72:96-9 
7.  Waschbisch A, Kallmunzer B, Schwab S, et al. Demyelinating disease and anti-NMDAR IgG 
antibodies: a case report. Ann Neurol 2014; 75(3): 411–428 
8.  Armangue T, Titulaer MJ, Málaga I, et al. Pediatric anti-N-methyl-D-
aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. J 
Pediatr. 2013 Apr;162(4):850-856  
  
 
 
